MedTrace Logo

Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

NCT00128310 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2023-05-31

No results posted yet for this study

Summary

This is a multicenter, randomized, prospective, Phase III study in which patients with advanced breast carcinoma previously treated with anthracyclines and taxanes will be randomly assigned to receive one of two treatment options: vinorelbine (Arm A) or gemcitabine plus vinorelbine (Arm B).

Conditions

Interventions

DRUG

Vinorelbine

DRUG

Gemcitabine

Sponsors & Collaborators

Principal Investigators

  • Study Director · Hospital San Carlos, Madrid

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-01-18
Primary Completion
2006-08-15
Completion
2008-01-24

Countries

  • Spain
  • Venezuela

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00128310 on ClinicalTrials.gov